Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia  Date: 2021-03-25

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07321332, are currently being conducted in the U.S.

The new drug pertains to the protease inhibitor class of antiviral drugs and can prevent viral replication in human cells, by blocking the production of an enzyme. For those unaware, protease inhibitors are commonly used for the treatment of viral pathogens like Hepatitis C and HIV.

Chief Scientific Officer of Pfizer, Mikael Dolsten reportedly said that both modes of prevention using vaccines and treatment for those affected with the virus are equally important to manage the coronavirus pandemic. The rapid mutation of SARS-CoV-2 along with the continued impact of the ongoing pandemic has necessitated access to curative measures in the long run.

The phase one trials for the oral antiviral drug are being performed in tandem with Pfizer’s development of PF-07304814, an intravenously administered protease inhibitor. The drug is currently in a phase 1 B clinical trial and is currently being tested on patients admitted in hospitals with COVID-19.

Even though drugmakers such as BioNTech and Pfizer have had their vaccines approved in the United States, analysts opine that the world will require a variety of drugs to arrest the pandemic.

Meanwhile, preclinical studies have exhibited that the oral drug, which is the first protease inhibitor to be analyzed in clinical trials, has a strong antiviral capacity against the virus, according to the firm.

The drug may be recommended to individuals who are newly infected with the virus as it can be ingested orally. Researchers hope that the drug will slow the progression of the disease and keep people out of the hospital.

Pfizer divulged that it would provide more information on the drug’s progress on 6th April 2021 at the American Chemical Society Spring Meeting.

Source Credit –

https://www.news18.com/news/world/pfizer-starts-early-stage-clinical-trial-testing-of-oral-antiviral-drug-for-coronavirus-report-3566318.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...